FindTrial
Sign In

Alemtuzumab (Campath)

DRUG5 trials

Sponsors

National Cancer Institute (NCI), National Institute of Neurological Disorders and Stroke (NINDS), National Heart, Lung, and Blood Institute (NHLBI), Dana-Farber Cancer Institute

Conditions

Chronic Graft-vs.-Host DiseaseLymphoma, Extranodal NK-T-CellLymphoma, T-CellMyelodysplastic SyndromesMyositis, Inclusion BodyT-LGL Lymphoproliferative Disorders

Phase 1

Campath in Chronic GVHD
CompletedNCT00495755
Dana-Farber Cancer InstituteChronic Graft-vs.-Host Disease
Start: 2007-07-31End: 2012-10-31Updated: 2013-08-09

Phase 2

Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
CompletedNCT00069238
National Cancer Institute (NCI)Lymphoma, Extranodal NK-T-Cell, Lymphoma, T-Cell
Start: 2003-09-19End: 2021-03-17Updated: 2022-02-24
Alemtuzumab to Treat Sporadic Inclusion Body Myositis
CompletedNCT00079768
National Institute of Neurological Disorders and Stroke (NINDS)Myositis, Inclusion Body
Start: 2004-03-31End: 2007-03-31Target: 20Updated: 2010-06-17
A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome
CompletedNCT00217594
National Heart, Lung, and Blood Institute (NHLBI)Myelodysplastic Syndromes
Start: 2005-07-21End: 2017-02-06Updated: 2018-10-30
Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
CompletedNCT00345345
National Heart, Lung, and Blood Institute (NHLBI)T-LGL Lymphoproliferative Disorders
Start: 2006-10-17End: 2020-10-27Updated: 2022-05-03

Related Papers

Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment
Blood Advances2022-07-2715 citations
Hijacking the Pathway: Perspectives in the Treatment of Mature T-cell Leukemias
HemaSphere2021-06-015 citations
Single Cell RNA Sequencing and V(D)J Profiling of T-Cell Large Granular Lymphocytosis
Blood2018-11-29
A Plasma microRNA Signature As a Biomarker for Acquired Aplastic Anemia
Blood2016-12-021 citations
Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.
2015-12-1741 citations
Alemtuzumab Achieved Durable Hematologic Response In Heavily Treated T-Large Granular Lymphocytosis Irrespective To STAT3 Mutation Or V-Beta Clone Size
Blood2013-11-15